相关实验视频

Updated: Sep 11, 2025

Inhibition of Aspergillus flavus Growth and Aflatoxin Production in Transgenic Maize Expressing the α-amylase Inhibitor from Lablab purpureus L.

Inhibition of Aspergillus flavus Growth and Aflatoxin Production in Transgenic Maize Expressing the α-amylase Inhibitor from Lablab purpureus L.

Published on: February 15, 2019

来自酶上化花生粉的α-葡萄糖酶抑制的特征和有效性

Sen Zhou¹, Zhiran Zhang¹, Shengxin Li¹

¹Qingdao University, Qingdao 266071, China.

Food research international (Ottawa, Ont.)

|August 12, 2025

概括

花生 (PEP) 通过抑制α-葡萄糖酶和改善小鼠的葡萄糖和脂质代谢,显示出治疗2型糖尿病的巨大潜力. 特定的PEP微分提供了有前途的抗糖尿病药物候选者.

科学领域:

生物化学生物化学
药理学药理学是指药理学的学科.
食品科学食品科学食品科学

背景情况:

具有α-葡萄糖酶抑制活性的天然物质对糖尿病治疗具有前景.
花生粉 (PM) 是这种生物活性化合物的潜在来源.

研究的目的:

为了研究酶化化花生粉 (PEP) 的α-葡萄糖酶酶抑制活性.
在2型糖尿病小鼠模型中评估PEP的抗糖尿病作用.
为了在PEP中识别具有高α-葡萄糖酶结合能力的特定.

主要方法:

微粒的酶性水解和超过以获得PEP分量.
在体外α-葡萄糖酶抑制试验.
在体内研究,使用高脂肪饮食/链毒素诱导的2型糖尿病小鼠模型.
免疫组合化学和西部斑点分析以调查信号通路.
对于的识别和结合分析,LC-MS/MS和分子对接.

主要成果:

在3kDa-500Da范围内的PEP显示出优异的α-葡萄糖酶抑制活性 (69.5%),产率 (85.75%),和含量 (1.55 mg/mL).
高剂量的PEP (PEP-H) 有效地降低了血糖和脂质水平,缓解了肝损伤,并改善了小鼠的2型糖尿病症状.
通过PI3K/Akt/GSK-3β信号通路调节PEP的肝脏葡萄糖和脂质代谢.
四种 (AFPKFR, APPFDPNKPK, PFPIK, FATPVPLPK) 被确定具有强烈的α-葡萄糖酶结合; APPFDPNKPK和FATPVPLPK通过混合类型的抑制表现出最高的抑制活性 (64.3%和75.4%).

结论:

微粒的酶化水解产生强大的α-葡萄糖酶抑制剂,具有显著的抗糖尿病作用.
通过改善代谢参数和调节关键信号通路,PEP显示了治疗2型糖尿病的治疗潜力.
特定的鉴定代表了开发抗糖尿病药物和功能性食品的新型候选人.

关键词:

在糖尿病小鼠中.葡萄糖和脂质的新陈代谢.分子对接是分子对接.这是一个花生花生,花生花生.这是一种α-葡萄糖酶抑制剂.

更多相关视频

RNAi-mediated Control of Aflatoxins in Peanut: Method to Analyze Mycotoxin Production and Transgene Expression in the Peanut/Aspergillus Pathosystem

RNAi-mediated Control of Aflatoxins in Peanut: Method to Analyze Mycotoxin Production and Transgene Expression in the Peanut/Aspergillus Pathosystem

Published on: December 21, 2015

A RAPID Method for Blood Processing to Increase the Yield of Plasma Peptide Levels in Human Blood

A RAPID Method for Blood Processing to Increase the Yield of Plasma Peptide Levels in Human Blood

Published on: April 28, 2016

相关概念视频

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...